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Abstract
Background
In light of the accelerating and rapidly evolving overdose crisis in the United States (US),
new strategies are needed to address the epidemic and to efficiently engage and retain indi-
viduals in care for opioid use disorder (OUD). Moreover, there is an increasing need for
novel approaches to using health data to identify gaps in the cascade of care for persons
with OUD.
Methods and findings
Between June 2018 and May 2019, we engaged a diverse stakeholder group (including
directors of statewide health and social service agencies) to develop a statewide, patient-
centered cascade of care for OUD for Rhode Island, a small state in New England, a region
highly impacted by the opioid crisis. Through an iterative process, we modified the cascade
of care defined by Williams et al. for use in Rhode Island using key national survey data and
statewide health claims datasets to create a cross-sectional summary of 5 stages in the cas-
cade. Approximately 47,000 Rhode Islanders (5.2%) were estimated to be at risk for OUD
(stage 0) in 2016. At the same time, 26,000 Rhode Islanders had a medical claim related to
an OUD diagnosis, accounting for 55% of the population at risk (stage 1); 27% of the stage 0
population, 12,700 people, showed evidence of initiation of medication for OUD (MOUD,
stage 2), and 18%, or 8,300 people, had evidence of retention on MOUD (stage 3). Imputa-
tion from a national survey estimated that 4,200 Rhode Islanders were in recovery from
OUD as of 2016, representing 9% of the total population at risk. Limitations included use of
self-report data to arrive at estimates of the number of individuals at risk for OUD and using
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Conclusions
Our findings indicate that cross-sectional summaries of the cascade of care for OUD can be
used as a health policy tool to identify gaps in care, inform data-driven policy decisions, set
benchmarks for quality, and improve health outcomes for persons with OUD. There exists a
significant opportunity to increase engagement prior to the initiation of OUD treatment (i.e.,
identification of OUD symptoms via routine screening or acute presentation) and improve
retention and remission from OUD symptoms through improved community-supported pro-
cesses of recovery. To do this more precisely, states should work to systematically collect
data to populate their own cascade of care as a health policy tool to enhance system-level
interventions and maximize engagement in care.
Author summary
Why was this study done?
• In the US, drug overdose represents a leading cause of accidental death. In light of this
growing epidemic, frameworks are needed to understand how to improve health sys-
tems to identify and engage individuals with substance use disorders in evidence-based
treatment modalities.
• Cascades of care have been used to track and improve population health outcomes for
multiple complex health conditions by encouraging data-driven policy decisions to
adapt and strengthen systems of care for how these conditions are managed, but few
cascades of care are available for use for local jurisdictions addressing opioid use disor-
der (OUD).
What did the researchers do and find?
• We engaged a group of stakeholders—local experts on opioid use and its consequences,
leaders from state agencies governing health and social services, directors of nongovern-
mental organizations providing health and social services to people living with OUD,
and community advocates with lived experiences of OUD and recovery—to adapt and
define a cascade of care for OUD for use in Rhode Island.
• The stakeholder engagement process resulted in a cascade of care with 5 stages, begin-
ning with individuals at risk for OUD (stage 0), continuing to individuals who are diag-
nosed with OUD (stage 1) and establish engagement with a medication-based treatment
plan (stage 2), and ending with continuous engagement with this treatment plan (stage
3) and recovery (stage 4).
• Using national survey estimates and statewide administrative claims databases, we
found that 26,000 Rhode Islanders were diagnosed with OUD (stage 1) in 2016, 12,700
people showed evidence of treatment initiation (stage 2), and 8,300 had evidence of con-
tinuous engagement with treatment for at least 6 months (stage 3). Based on a national
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survey estimate, about 4,200 individuals are estimated to have achieved recovery from
OUD using medications (stage 4).
What do these findings mean?
• Engagement with a diverse group of stakeholders can result in the development of a cas-
cade of care to assess and measure the success of statewide health systems in delivering
interventions to address opioid-related harms. The cascade of care can be used as a
framework to strengthen health systems that may result in reductions in the number of
individuals at risk for OUD and increases in the number of individuals with OUD who
are able to achieve long-term recovery.
• The estimates of the numbers of individuals in each stage represent a static “snapshot”
and are considered preliminary; further efforts are needed to fine-tune these propor-
tions. For example, limitations included having to use the definition of recovery and
estimates used in the National Recovery Survey, as there are currently no statewide data
sources for measuring recovery. Further research is needed to understand how to best
define and operationalize this stage at a statewide level.
Introduction
As the drug overdose crisis in the US continues to accelerate [1], new strategies are needed to
address the epidemic and to more efficiently engage and retain individuals with substance use
disorder in care. Applying a cascade of care framework offers a novel approach to curb this
unrelenting crisis of drug-related harms by identifying novel points for intervention at the sys-
tem level [2]. Cascades of care have been used to track and improve population health out-
comes for multiple complex health conditions [3–14], with the most well-known and visible of
such being the continuum of care for HIV infection [4,9,10,12–14]. Applying this continuum
of care framework has drastically improved health outcomes among people living with HIV
infection, encouraged data-driven policy decisions, and brought about revolutionary system-
level changes worldwide in how HIV infection is managed across the course of the disease
[12–14].
Researchers and policymakers have called for a cascade of care framework to be applied to
understand gaps in treatment engagement among those experiencing substance use disorder,
and opioid use disorder (OUD) in particular [2,15,16]. Specifically, a new framework for
assessing the availability and quality of care for OUD has recently been defined by Williams
and colleagues using metrics defined by the National Quality Forum and the Agency for
Healthcare Research and Quality [17]. Preliminary evidence suggests that improvements in
health delivery processes at a system level are linked to improved health outcomes and lower
mortality among patients with OUD [18]. Defining a cascade of care is a critical first step in
helping local jurisdictions establish and utilize their data resources to inform policy and pro-
mote interventions that protect against the potentially deadly harms of OUD when left
untreated [15,19]. Herein, we aim to adapt and apply the cascade of care defined by Williams
and colleagues [20] for the use of medication for OUD (MOUD) [21], using key national and
statewide datasets for Rhode Island, a small state in New England, a region of the US heavily
affected by the opioid crisis [1].
Defining a recovery-oriented cascade of care for opioid use disorder
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Methods
Study setting
Rhode Island is an ideal setting for local adaptation of a cascade of care framework for OUD,
given ongoing cross-agency, statewide policy efforts to curb the overdose crisis, and the avail-
ability of statewide health claims data to evaluate OUD care [22]. Since 2014, state agencies
and community leaders have engaged in data sharing and multidimensional surveillance of
the opioid crisis [23]. Beginning in 2015, the statewide Overdose Prevention and Intervention
Task Force has led the creation and implementation of the Overdose Prevention and Interven-
tion Action Plan [22], designed to monitor key health metrics and guide data-driven program
delivery to help end the overdose crisis in the state [22].
Stakeholder engagement
Given that a large amount of programmatic and surveillance data were already being collected
and shared on the state’s publicly accessible overdose data dashboard, PreventOverdose, RI
(https://preventoverdoseri.org/), to assess progress towards the goals of the action plan [23],
key state agency partners engaged with a team at Brown University beginning in June 2018 to
begin developing a statewide cascade of care for people living with OUD. These evaluation
activities did not meet the federal definition of research, and, as such, ethics approval was not
required. The stakeholder group involved 28 members, including local experts on opioid use
and its consequences, leaders from state agencies governing health and social services, direc-
tors of nongovernmental organizations providing health and social services to people living
with OUD, and community advocates with lived experiences of OUD and recovery. This
group met 7 times between June 2018 and May 2019 and developed the proposed cascade of
care for Rhode Island through an iterative process. Prior to discussions designating the specific
stages of the cascade of care, the stakeholder group agreed on a set of shared terminology
(Table 1) and identified shared values to guide the framework development process. There
were no prespecified plans for defining the stages of the cascade of care or the data sources
Table 1. Glossary of terms guiding the framework development process.
Term Definition
Cascade of care A cascade of care [2,14,15,24,25] is a conceptual framework to guide and track
patients (people) over time through stages of medical care for a particular disease or
condition, allowing for identification of key points or places to intervene and improve
health outcomes [2].
Opioid use disorder (OUD) We use OUD as the overarching medical condition to define the population of people
measured in the cascade of care through an OUD diagnosis. OUD is also used to
identify the healthcare systems (places) and transition points (processes) relevant for
engaging people at each stage of the cascade [26].
Criteria for OUD We use Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for
diagnosing OUD, which is defined by loss of control of opioid use, risky opioid use,
impaired social functioning, tolerance, and withdrawal symptoms from opioids
[27,28].
Indicators Indicators are the “units of service” or “process measures” in the datasets, which are
the details that help us define the size of each stage in the cascade of care, as compared
to other stages. They also allow us to assess the quality of referrals and retention from
one stage to the next [18,29–32].
Screening and assessment
for OUD
Evidence-based screening instruments (secondary prevention) that can be used at
point of care (such as a clinic) to help identify someone experiencing opioid misuse or
OUD. Examples include the Screening, Brief Intervention, and Referral to Treatment
(SBIRT) or the National Institute on Drug Abuse (NIDA)–modified Alcohol,
Smoking and Substance Involvement Screening Test (ASSIST) [33,34].
https://doi.org/10.1371/journal.pmed.1002963.t001
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used to estimate the current state of the cascade of care prior to this stakeholder engagement
process. All methods discussed below have been described in line with the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) Statement (see S1 STROBE
Checklist).
Later discussions designating the specific stages of the cascade of care were grounded in the
framework proposed by Williams and colleagues in 2017, which was updated in 2019 [15,20].
This cascade includes 4 stages, beginning with stage 1, where individuals are already identified
as having OUD or experiencing a nonfatal overdose [15,20]. The first stage, engagement in
care, is defined as the proportion of individuals with OUD who receive specialty services in a
given year [20]. The second stage, MOUD initiation, is defined as the percentage of individuals
in care who receive MOUD at least once [20]. The third stage, retention, is defined as the pro-
portion of individuals who receive MOUD who continue to do so for at least 180 days [20].
The fourth stage, remission, is defined as the proportion of retained individuals who no longer
meet diagnostic criteria for OUD [20].
With this framework informing the foundation of the adapted cascade of care, stakeholders
were presented with the available measures of healthcare access and quality to represent each
stage [16,17] and discussed the feasibility of using these metrics to develop a “snapshot” of the
current state of the cascade of care for OUD in Rhode Island in the year 2016. This process led
to additional refinements to the cascade and finalization of the operational definitions of each
stage while also helping to define the target population (e.g., those experiencing OUD) and the
healthcare systems and data-sharing partners for the cascade [20,26]. By using national quality
metrics, the cascade could be designed to enhance existing statewide policy and surveillance
tools by (1) creating an annual measure of statewide engagement in care using available data-
sets, (2) setting targets and standards for improving linkages across stages of care, and (3)
defining successful endpoints for treatment of OUD through consensus among the stakehold-
ers [17,18,29,30].
Results
Identifying the guiding principles of a cascade of care for OUD
The stakeholder engagement process resulted in a set of guiding principles for the cascade of
care. Through this community-driven process, stakeholders determined that a cascade of care
for OUD should be
• Measurable and achievable: The cascade of care should track statewide progress in connect-
ing people to high-quality OUD care by identifying meaningful stages of engagement in care
and defining measurable targets for engagement in care at each of its stages.
• Timely and dimensional [35]: The cascade of care should measure statewide progress year
over year using input from multiple datasets and systems of care. This includes measuring
the estimated number of patients in each stage at regular intervals and assessing their prog-
ress in moving from one stage to the next.
• Incremental: The cascade of care should be used to increase impact at the population level.
Through this lens, interventions moving larger groups of individuals to a subsequent stage
should be prioritized, rather than moving small numbers of individuals immediately to the
end stages of the cascade.
• Inclusive: The definition of successful progress through the cascade of care should be client-
centered and inclusive of available evidence-based treatment modalities, patient requests,
and provider opinions.
Defining a recovery-oriented cascade of care for opioid use disorder
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• Voluntary: Individuals counted in the cascade should be those who voluntarily entered
treatment.
• Equitable: Comprehensive analyses of health delivery processes have the capacity to uncover
patterns of previously unseen inequities across health systems, across demographic groups,
among special populations, or across stages of care. Inequalities that appear as systemic bar-
riers to successful progress along the cascade should be investigated and responded to as
they arise.
Defining the stages of the cascade of care for OUD
In the preliminary framework proposed by Williams and colleagues [20], “remission” is
defined as a finite endpoint, similar in spirit to viral load suppression in the context of the con-
tinuum of care for HIV infection [9]. However, OUD was conceptualized by our stakeholder
group as a chronic brain disease [36] (rather than as a chronic infection) that has the potential
for both relapse and recovery, and where persons are subject to movement in and out of sys-
tems of care. As such, our stakeholder group sought to capture more than a single clinical end-
point for the final stage, given that clinical records indicating symptom remission, or absence
of evidence of recurrence (e.g., an emergency department visit for a drug overdose) did not
fully capture the spectrum of engagement in care for and recovery from OUD. Further, while
retention on MOUD represents one element of successful treatment, stakeholders felt that
measuring engagement in recovery support services [37,38], including those offered in outpa-
tient healthcare settings and those offered by peers in the community, was critical for measur-
ing long-term absence of OUD symptoms.
With this perspective, the long-term goal of the cascade of care developed by the stake-
holder group (hereafter referred to as the Rhode Island Cascade of Care for Opioid Use Disor-
der) was 2-fold. Similar to the framework proposed by Williams and colleagues [20], the
organization of the cascade reflects a primary prevention goal of reducing the number of indi-
viduals at risk for OUD (stage 0), while also increasing the number who remain active in their
recovery through engagement with professional and peer-based support services (stage 4). The
stages of the Rhode Island Cascade of Care for Opioid Use Disorder are defined below (Fig 1).
Stage 0 includes those who are considered at risk for OUD and represents the population
who may benefit from targeted prevention efforts and/or early intervention services. Individu-
als in this stage may meet the diagnostic criteria for a clinical diagnosis of OUD at some point
during their use, but many may not. Furthermore, this heterogeneous group may include
treatment-naïve individuals as well as individuals who were at some point in recovery from
OUD. Therefore, the long-term goal is to reduce the total population at risk for OUD over
time through a combination of primary prevention efforts (e.g., improved opioid prescribing
guidelines to prevent misuse of prescription opioids) as well as secondary prevention efforts
(e.g., early intervention through routine screening and rapid referral) [20]. This stage was
operationalized as the number of people who reported using heroin and/or misusing a pre-
scription opioid (i.e., using a prescription opioid without a prescription or in any way other
than as described by a doctor) in the past 12 months, consistent with measures in the National
Survey on Drug Use and Health (NSDUH) [39].
Stage 1 represents those diagnosed with OUD. This stage is operationalized as the number
of individuals with a medical claim tied to a diagnosis of OUD in a given year, based on exist-
ing national quality metrics [17].
Stage 2 represents unique individuals who have initiated MOUD. The national quality met-
rics suggest including only those individuals who have been on MOUD for more than 7 days
Defining a recovery-oriented cascade of care for opioid use disorder
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at one time (representing stabilization) but have been engaged for less than 180 days [29,30];
those who have been engaged for 7 days or less would remain in stage 1. Although we acknowl-
edge other modalities of treatment for OUD, the stakeholders chose to focus on MOUD given
strong evidence supporting its effectiveness [40–42] and the available datasets on prescribing
and dispensing of these medications to persons with OUD.
Stage 3 represents those who are retained on MOUD. Based on existing national quality
metrics [30,43], persons who are retained have engaged with their treatment plan for 180
days or longer at one time, without a gap of more than 7 days. The goal in moving
Fig 1. Overview of the Rhode Island model for the cascade of care for opioid use disorder (OUD). Credit: Maxwell
Krieger, Brown University.
https://doi.org/10.1371/journal.pmed.1002963.g001
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individuals to this stage is to support continuous engagement with treatment services for at
least 6 months.
Stage 4 represents recovery from OUD. In the context of this cascade of care, recovery is
defined as having achieved sustained remission from or resolution of symptoms of OUD using
a MOUD-assisted pathway [37,38,44]. The goals for this stage are prevention of OUD symp-
tom recurrence and support of active recovery through structural interventions (e.g., housing,
employment programs) and engagement with recovery community centers and community-
based peer support services. Stakeholders noted the challenges of measuring the size of this
population in existing datasets, but noted that this stage may be measured by considering indi-
viduals who have engaged with MOUD for at least 180 days as synonymous with those who
are in recovery in the absence of additional data, or by supporting primary data collection
activities where self-reported recovery from OUD is captured in ongoing statewide health
assessments.
The arrows at the bottom of Fig 2 represent possible transitions through the cascade in 1
year. For example, individuals who are diagnosed with OUD in a given year may initiate
MOUD, be retained in care, and achieve recovery. Persons who meet the definition of recovery
may become at risk again, thus transitioning back to stage 0 (if never formally diagnosed) or
Fig 2. Results for the Rhode Island Cascade of Care. Stages 0 and 4 represent estimates from national survey data sources. Stage 1
represents statewide claims data from the HealthFacts RI all-payer claims database (APCD). Stages 2 and 3 represent combined
estimates from the Rhode Island Prescription Drug Monitoring Program (PDMP) and the Behavioral Health On-Line Database
(BHOLD), which include treatment claims for methadone and records for buprenorphine prescriptions. All estimates are
approximate and considered preliminary. Credit: Maxwell Krieger, Brown University.
https://doi.org/10.1371/journal.pmed.1002963.g002
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stage 1 (if ever formally diagnosed). Some people may exit the population entirely without pro-
gressing beyond stage 0 (i.e., through cessation of drug use), as shown by the leftmost arrow.
Preliminary estimation of the Rhode Island Cascade of Care for Opioid Use
Disorder
A preliminary estimation of the number of individuals included in each stage of the Rhode
Island Cascade of Care for Opioid Use Disorder is displayed in Fig 2.
Identifying the number of individuals included in stage 0 leverages data collected as part of
NSDUH. This survey has been conducted by the US Department of Health and Human Ser-
vices since 1971. Each year, about 70,000 people aged 12 years and older are interviewed to
provide self-reported information on alcohol, tobacco, and drug use; mental health; and other
health-related issues [39]. The Restricted-use Data Analysis System (R-DAS) was launched by
the Substance Abuse and Mental Health Services Administration (SAMHSA) as an online ana-
lytic system that allows analysts to produce cross-tabulations using restricted-use NSDUH
datafiles [39]. R-DAS allows for the creation of state-level estimates of select variables using
revised weights and combining multiple years of data collection [44]. Using R-DAS, we calcu-
lated an estimate for the combined total number of people who reported heroin use and/or
misuse of a prescription opioid in the past 12 months in Rhode Island. This population esti-
mate combines data from 2015 and 2016 and, as such, is meant to be representative of the aver-
age annual population across the 2 years. Based on this analysis, we estimate that there were
47,000 (95% CI 33,250–60,700) people in Rhode Island in stage 0 in 2016. This estimate serves
as the cross-sectional denominator for the Rhode Island Cascade of Care for Opioid Use
Disorder.
Identifying the number of individuals included in stage 1 utilized data from HealthFacts RI,
the state’s APCD. The APCD stores information on enrollment, medical claims, pharmacy
claims, and healthcare providers from privately insured individuals as well as Medicare and
Medicaid recipients [45]. Following the Supreme Court ruling in Gobeille v. Liberty Mutual
Insurance Company in 2016, the APCD does not include information on individuals with self-
funded employee health plans (i.e., those who are self-insured), representing about 20% of
Rhode Islanders. Individuals included in stage 1 included those with active claims in 2016
using ICD-9-CM codes 304.00–304.03 (opioid dependence), 304.70–304.73 (dependence com-
binations of opioid type drug with any other), and 305.50–305.53 (opioid abuse) and using
ICD-10 codes F11.1x (opioid abuse), F11.2x (opioid dependence), and F11.9x (opioid use,
unspecified). Based on this data source, we estimated that there were 26,000 people in Rhode
Island in stage 1 in 2016, representing an estimated 55% of people at risk for OUD (stage 0).
Identifying the number of individuals in stage 2 utilized data from PDMP and BHOLD, 2
databases maintained by the Rhode Island Department of Health and the Rhode Island
Department of Behavioral Healthcare, Developmental Disabilities and Hospitals, respectively
[46,47]. Using these data, we calculated the number of unique individuals receiving metha-
done or buprenorphine for more than 7 days at one time in 2016. Based on these sources, we
estimated that there were 12,700 people in Rhode Island in stage 2, representing an estimated
27% of people at risk for OUD (stage 0) and 49% of people diagnosed with OUD (stage 1).
Identifying the number of individuals in stage 3 also utilized data from PDMP and BHOLD
[46,47]. Using these datasets, we identified unique individuals who were engaged with MOUD
through a certified opioid treatment program or prescribed buprenorphine for at least 180
days without a gap of more than 7 days based on the date of first service. Individuals meeting
the criteria for retention at any point in 2016 were included. Based on these data sources, we
estimated that there were approximately 8,300 people in Rhode Island who progressed to stage
Defining a recovery-oriented cascade of care for opioid use disorder
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3 through the use of methadone or buprenorphine, representing an estimated 18% of people at
risk for OUD (stage 0) and 65% of people who initiated MOUD (stage 2).
Identifying the number of individuals in stage 4 utilized data from the National Recovery
Survey conducted in 2016 by Kelly et al. [37]. The National Recovery Survey was a national
probability-based sample of adults in the US who self-identified as having resolved a signifi-
cant problem with alcohol and other drugs [37]. Individuals who answered “Yes” to the ques-
tion “Did you used to have a problem with drugs or alcohol, but no longer do?” were
identified as being in recovery. Based on the survey response to this screening question, these
individuals were estimated to represent 9.1% of the adult population of the US (95% CI 8.6%–
9.6%). Among individuals who achieved recovery, 5.3% were estimated to have achieved
recovery from an opioid problem (95% CI 3.8%–6.8%) using MOUD [38]. In applying these
estimates to the adult population of Rhode Island, we estimated that there were 4,200 people
(95% CI 2,900–5,600) in Rhode Island who achieved recovery through use of MOUD, repre-
senting 9% of people at risk for OUD and 50% of people retained on MOUD (stage 3).
Discussion
Using a combination of national and statewide databases, we were able to generate a statewide,
cross-sectional cascade of care for the treatment of OUD in Rhode Island beginning with
those at risk for OUD and ending with those in recovery from OUD. Initial estimates of the
number of individuals in each stage indicated that Rhode Island has high initiation and reten-
tion rates for engagement with MOUD following a diagnosis with OUD. This is consistent
with 2017 data from the National Survey of Substance Abuse Treatment Services, which
showed that Rhode Island had a rate of 419 per 100,000 people aged 18 years and older
engaged with MOUD, ranking among the top 5 states in the nation [48]. However, the results
also indicate that additional efforts, such as enhanced screening, are needed to identify those at
risk and engage them in care to achieve the dual purpose of mitigating potential harms of opi-
oid use and increasing opportunities for diagnosis and treatment of OUD symptoms. In addi-
tion, promoting and supporting continuous engagement with MOUD modalities may provide
additional protection against the potential harms of opioid use among those who initiate
MOUD but are not retained [49,50].
In the process of developing and defining the Rhode Island Cascade of Care for Opioid Use
Disorder, stakeholders expressed the importance of inclusive, community-led prevention
efforts, similar to those described by Williams and colleagues [20]. Stakeholders focused on the
goal of measuring those at risk for OUD (stage 0) because of the growing efforts to incorporate
primary and secondary prevention interventions for this population within the treatment-ori-
ented portions of the cascade of care. In addition, stakeholders acknowledged that movement
through the cascade may not be linear, but will likely be cyclical given that both relapse and
recovery occur in the context of OUD [36]. Having the ability to provide a specific target for
the size of the population to be reached by system-level prevention efforts may lead to more
effective means of engaging this population with both prevention and treatment services. The
estimated size of this population (5.2% of people in Rhode Island) is similar to that reported in
a recent study in the neighboring state of Massachusetts by Barocas and colleagues (4.6% in
2015) [51].
Initiation and continuous engagement with MOUD are critical steps in the cascade of care.
Rhode Island has steadily increased capacity for MOUD enrollment as part of its Overdose
Prevention and Intervention Action Plan, but full engagement with treatment programs con-
tinues to represent a statewide challenge. Prior work has identified system-level interventions
to address this gap in care, including increasing low-barrier access and initiation of MOUD in
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settings such as the emergency department [52,53]. Other interventions focus on increasing
clinical training and education on buprenorphine prescription to increase the number of set-
tings where people can initiate MOUD [52,54]. Based on preliminary estimates, it is estimated
that about one-half of individuals with a diagnosis of OUD (stage 1) initiate MOUD (stage 2).
This estimate is slightly higher than that reported by Larochelle and colleagues in the neigh-
boring state of Massachusetts, where about one-third of individuals who experienced a nonfa-
tal overdose later initiated methadone, buprenorphine, or naltrexone use in the following 12
months [55].
Stakeholders further identified the critical step of including and therefore measuring recov-
ery-oriented systems of care and engagement with community-based recovery supports. There
is additional value added to the model put forth by Williams and colleagues [15,20] by incor-
porating this stage as it captures a positive endpoint of OUD for many people. However, mea-
suring recovery remains a challenge. The estimate we included in the initial parameterization
for the cascade of care comes with some uncertainty. Engagement with recovery support ser-
vices could be measured more precisely through referrals to community-based recovery sup-
ports such as peer recovery coaches, recovery-friendly employment programs, or recovery
housing [37,56–58]. Measuring recovery or engagement with recovery support services is
important for identifying interventions and capturing the protective factors associated with
achieving and maintaining such a status, including the empowerment and resource capital
that is inherent in recovery [38,59–63].
Currently, there is no existing population-based data source that allows us to measure the
number of people who identify as being in recovery at the state level. The Behavioral Risk Fac-
tor Surveillance System, a national survey conducted annually by the Centers for Disease Con-
trol and Prevention, could add an optional module to achieve this aim [64]. The State of
Oregon is using this approach by adding a module with items from the National Recovery Sur-
vey [37,56]. This approach offers a more consistent data source collected on an annual basis
using the same validated items from the National Recovery Survey. In addition, states may
consider implementing assessment of recovery at the clinical level by integrating annual
screening tools into existing systems of care such as the Brief Assessment of Recovery Capital
(BARC-10) [63,65,66], This scale offers a snapshot of 10 recovery measures that are indicative
of someone’s progression in their recovery from OUD [63,65,66]. Use of such a scale provides
an opportunity to more accurately estimate the size of the population in the final stage of the
cascade.
There are implications for how interventions may be applied to improve transitions
between the stages, particularly if the goal is to maximize reduction in drug overdose deaths.
Examples may include enhanced screening for OUD if a substantial drop between stages 0 and
1 is observed, increased initiation of MOUD for people diagnosed with OUD to address gaps
between stages 1 and 2, deployment of case management interventions to improve retention
in care to improve progress from stage 2 to stage 3, and providing funding for community-
based recovery support services (e.g., housing, employment training programs) to move indi-
viduals from continuous use of MOUD (stage 3) to long-term recovery (stage 4) [52].
Limitations
The primary goal of the current study was to develop and operationalize a statewide cascade of
care for OUD, resulting in a “breadth of scope” hybrid model of unlinked data sources [26]
offering a cross-sectional snapshot of the number of individuals in each stage. This limits our
ability to fully understand the trajectories of specific individuals across all stages or account for
true transitions from one stage to the next, particularly from stage 0 to stage 1 and from stage 3
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to stage 4. For stage 0, we also recognize that there are limitations inherent in using self-
reported measures of heroin use and prescription opioid misuse, including social desirability
bias, where individuals who use heroin or misuse prescription opioids may report not doing
so to avoid perceived judgment. Furthermore, recovery (stage 4) is often a self-identified status
that is difficult to measure through administrative claims data due to potential overlap with
other stages (i.e., those with long-term engagement with MOUD in stage 3) [67]. Future analy-
ses will focus on improved linkages across datasets that account for movement between the
outlying stages (stages 0 and 4) and the system of care transition stages (stages 1, 2, and 3), and
the time-varying nature of the transition of individual patients from one stage to the next [67].
Given the challenges with unrelated, cross-sectional data sources, we ask that the descriptive
data and results be interpreted with caution.
Similarly, the Rhode Island Cascade of Care for Opioid Use Disorder is not representative
of detailed stages of OUD treatment nor is it inclusive of all available evidence-based treatment
modalities. Our focus was to first establish the stages that stakeholders agreed upon, and for
which we had access to the most complete data. For example, in stage 2 we used the number of
unique initiations of MOUD statewide; however, this does not include individuals who were
on MOUD while incarcerated [68]. Stages 2 and 3 also excluded extended-release injectable
naltrexone, for which there were fewer than 100 records in Rhode Island in 2016. In addition,
there are limitations with the current definition of recovery in stage 4 (“Did you used to have a
problem with opioids and no longer do?”) [38], as this may include individuals who would not
meet the diagnostic criterion for OUD or may not have progressed through the cascade to
reach this stage.
Conclusion
The Rhode Island Cascade of Care for Opioid Use Disorder provides statewide data-sharing
partners and policymakers with a starting point for understanding and assessing engagement
in care, a system-level “snapshot” for prioritizing the datasets that would be useful in measur-
ing the annual state of the system [14,17,26,56]. The 2 processes of undertaking a community-
driven stakeholder process and prioritizing available datasets to populate this new model
helped to operationalize and apply the cascade for the state. This process efficiently prioritized
and identified the scope of the population and defined the essential stages of engagement with
medication-based treatment for OUD. We succeeded in the original goal of operationalizing a
population-level cascade orientated around promoting recovery, and we can now use this
snapshot as a health policy tool to drive policy decisions and improve health outcomes across
the state.
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